ONL Therapeutics | Advancing Retinal Disease Therapies through Neuroprotection

News

ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings

February 4, 2025
ONL Therapeutics Appoints Penny Fleck as Chief Development Officer

January 7, 2025
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing

September 13, 2024
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight

September 10, 2024
ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference

February 6, 2024
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society

January 23, 2024
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

August 28, 2023
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

April 12, 2023
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 11, 2023

Privacy Statement | Accessibility Statement | Terms of Use | Copyright All Rights Reserved ©2025